LabTech(688056)2022-04-25 16:00Financial Performance - The company's operating revenue for 2021 was CNY 368.86 million, an increase of 5.81% compared to 2020[20]. - The net profit attributable to shareholders for 2021 was CNY 69.41 million, reflecting a growth of 6.44% year-on-year[20]. - The net profit after deducting non-recurring gains and losses was CNY 62.99 million, up by 7.99% from the previous year[20]. - The company's total assets at the end of 2021 were CNY 892.47 million, a 4.70% increase from 2020[21]. - The net assets attributable to shareholders increased by 6.27% to CNY 786.43 million at the end of 2021[21]. - Basic and diluted earnings per share for 2021 were CNY 1.04, down 11.11% compared to the previous year[22]. - The net cash flow from operating activities decreased by 41.25% to CNY 49.08 million, primarily due to increased inventory and supply chain disruptions[23]. - The company's operating costs for the reporting period were 190.19 million yuan, an increase of 6.17% compared to the same period last year, primarily due to rising commodity prices and adjustments in sales prices[118]. - The company's sales expenses amounted to 53.27 million yuan, up 13.93% year-on-year, driven by an increase in sales personnel and overall salary expenses rising by 16.63%[118]. Research and Development - The R&D expenditure as a percentage of operating revenue was 8.51%, slightly up from 8.42% in 2020[22]. - The company’s R&D investment reached 31.38 million yuan in 2021, a 6.95% increase compared to 2020, accounting for 8.51% of revenue[35]. - The company has established a postdoctoral research station to attract high-end talent and enhance its R&D capabilities[46]. - The company aims to enhance its technological capabilities and increase R&D investment to develop high-end instruments, leveraging national policies that support domestic instruments and import substitution[39]. - The company has developed several core technologies in analysis testing instruments, including fully automated solid-phase extraction and gel purification technologies, enhancing recovery rates and analysis accuracy[83]. Product Development and Innovation - The company launched a new product, the Inductively Coupled Plasma Mass Spectrometer (ICP-MS), in May 2021, achieving sales in semiconductor and medical fields[34]. - The company is developing two new projects related to ICP-MS, including the ICP-Q-TOF-MS, which is aimed at single-cell multi-element detection[36]. - The ICP-MS-MS project is focused on enhancing sensitivity and interference resistance for semiconductor applications[37]. - The company launched several new products during the reporting period, including the EV400H rotary evaporator and the HPSE-6 Ultra high-efficiency rapid solvent extractor, and received 21 new authorized patents and 2 software copyrights[38]. - The company has successfully integrated multiple sample pretreatment technologies into a single automated solution for clients[85]. Market Expansion and Sales Strategy - The company has established a broad sales network with subsidiaries in the US and Hong Kong, and has expanded into new industries such as nuclear and pharmaceutical sectors, while continuing to deepen its presence in traditional fields like environmental and food testing[40]. - The company is focusing on the development of new sample pretreatment products and analysis testing instruments to enhance its market position in food testing and environmental monitoring[71]. - The company plans to strengthen its sales team through specialized training to enhance professional knowledge and service capabilities[167]. - The company aims to achieve continuous revenue growth by increasing brand recognition and market share through diverse product offerings and efficient after-sales service[163]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from its accounting firm, indicating the financial statements are accurate and complete[5]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[7]. - There are no violations of decision-making procedures regarding external guarantees[8]. - The company has not disclosed any special arrangements for corporate governance[8]. - The company has held 3 shareholder meetings, 5 board meetings, and 4 supervisory board meetings during the reporting period, ensuring compliance with legal and regulatory requirements[173]. Financial Management and Shareholder Relations - The company plans to distribute a cash dividend of 3.50 RMB per 10 shares, totaling 23,450,000 RMB, which represents 33.78% of the net profit attributable to shareholders for 2021[5]. - The total number of shares held by the board members and senior management at the end of the reporting period is 32,063,370 shares, unchanged from the beginning of the year[180]. - The total pre-tax remuneration for the board members and senior management during the reporting period amounts to 9.65 million yuan[180]. - The company is focused on creating a harmonious development environment and improving investor relations through timely and accurate information disclosure[174]. Risk Management - The company has detailed the potential risks in its operations, which can be found in the "Management Discussion and Analysis" section of the report[4]. - The company faces risks related to market expansion, including potential adverse changes in cooperation with major distributors[108]. - The company is exposed to foreign exchange risks due to a significant portion of export business settled in USD and EUR[110].